hookipapharma.com (HOOK) - Long-Term Debt to Capital Coefficient

HOOKIPA Pharma Inc. (HOOK) focuses on developing cutting-edge methods to combat oncology and viruses, leveraging the success of HB-200 trials and its collaboration with Gilead. The stock price trend reflects dynamics at the 0.00 level. The business is based on the development of unique vaccines in high demand among major industry players. The company is successfully expanding its profile by utilizing viral technologies to stimulate T-lymphocytes.

The ratio is calculated as the proportion of liabilities with a maturity exceeding one year to total equity. This metric determines the degree of financial autonomy and the company's resilience to long-term credit risks. For HOOKIPA Pharma Inc. (HOOK), investments in robotic vector synthesis platforms require significant capital expenditures. By analyzing the long-term debt structure relative to equity, an investor assesses the balance between financial leverage and internal funds. Low values confirm the safety of developing high-tech immunological research.